Sutro Biopharma appoints Heidi Hunter as Class I director, effective Nov 19, 2021

SUTRO BIOPHARMA, INC.

Heidi Hunter appointed Class I director and member of Audit and Science & Technology Committees.
Receives pro rata annual retainers: $40K director, $10K audit, $5K science/tech.
Granted option for 24,000 shares vesting monthly over three years; 9,884 shares vesting until 2022 annual meeting.
Exercise price equals closing price on Nov 19, 2021.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Heidi Hunter

Class I director

STRO · SUTRO BIOPHARMA, INC.

Effective: 2021-11-19
Filed: November 17, 2021, 6:59 PM ET

On November 12, 2021, the board of directors (the “ Board ”) of Sutro Biopharma, Inc. (the “ Company ”) appointed Heidi Hunter, as a Class I director and member of the Audit Committee and Science and Technology Committee, effective as of November 19, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Heidi Hunter was appointed as Class I director at SUTRO BIOPHARMA, INC..

Action: appointed
Role: Class I director

Exact text from the filing

On November 12, 2021, the board of directors (the “ Board ”) of Sutro Biopharma, Inc. (the “ Company ”) appointed Heidi Hunter, as a Class I director and member of the Audit Committee and Science and Technology Committee, effective as of November 19, 2021.

View on SEC.gov

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001564590-21-057374

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.